Immunic, Inc. (IMUX)
NASDAQ: IMUX · IEX Real-Time Price · USD
+0.050 (3.55%)
Jul 22, 2024, 3:59 PM EDT - Market closed

Company Description

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany.

Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases.

Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Immunic, Inc.
Immunic logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 77
CEO Dr. Duane D. Nash J.D., M.B.A., M.D.

Contact Details

1200 Avenue Of The Americas, Suite 200
New York, X1 10036
Phone (332) 255-9818

Stock Details

Ticker Symbol IMUX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001280776
CUSIP Number 4525EP101
ISIN Number US4525EP1011
Employer ID 56-2358443
SIC Code 2834

Key Executives

Name Position
Dr. Daniel Vitt Ph.D. Chief Executive Officer, President and Director
Dr. Duane D. Nash J.D., M.B.A., M.D. Executive Chairman
Glenn Whaley CPA Chief Financial Officer
Dr. Andreas Muehler M.D., Ph.D. Chief Medical Officer
Dr. Hella Kohlhof Chief Scientific Officer
Jessica Breu Head of Investor Relations and Communications
Inderpal Singh General Counsel
Patrick Walsh Chief Business Officer

Latest SEC Filings

Date Type Title
Jul 9, 2024 8-K Current Report
Jul 2, 2024 S-8 Securities to be offered to employees in employee benefit plans
Jun 13, 2024 8-K Current Report
Jun 10, 2024 424B5 Filing
May 31, 2024 EFFECT Notice of Effectiveness
May 24, 2024 S-3/A [Amend] Registration statement under Securities Act of 1933
May 8, 2024 10-Q Quarterly Report
May 8, 2024 8-K Current Report
Apr 30, 2024 EFFECT Notice of Effectiveness
Apr 30, 2024 424B3 Prospectus